Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-1

Contributed by: Business Wire

Tags

Biotechnology
Diabetes
Health
Pharmaceutical
Clinical Trials
Diabetology Limited

More Like This

Over 55,000 people already on Simple Online Healthcare's waitlist for UK's first, newly approved oral GLP-1

PR Newswire associated0

Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

First GLP-1 tablet for weight loss approved in the UK

PR Newswire associated0

Wegovy® pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison to be presented at Obesity Medicine Association 2026

PR Newswire associated0

Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025

PR Newswire associated0

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions

PR Newswire associated0

FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event